Insmed INSM TPIP external R&D expenses — R&D

Other product segments

Similar metrics at other companies

WVEOther Research And Development Expenses Including PNPLA3Additional Preclinical Programs PRISM — Research And Development Expense

$36.65M+13.0%

LQD

LQDAGeneric Treprostinil — Program Expenses

-$49K-132%

DNLITherapeutics Segment — External research and development expense

$38.46M-8.4%

NRIXInternal research and development expenses — R&D

$56.56M+1.6%

DNLITherapeutics Segment — Research and Development Expense

$103.85M-10.7%

BCRXSTAR-0310 — Research and Development Expense (Excluding Acquired in Process Cost)

$683K—

Questions, answered.

What is Insmed's TPIP external R&D expenses — R&D?

Insmed (INSM) reported TPIP external R&D expenses — R&D of $37.34M in Q1 2026.

How has Insmed's TPIP external R&D expenses — R&D changed year-over-year?

Insmed's TPIP external R&D expenses — R&D increased by 308.0% year-over-year, from $9.15M to $37.34M.

What is the long-term trend for Insmed's TPIP external R&D expenses — R&D?

Over 3 years (2022 to 2025), Insmed's TPIP external R&D expenses — R&D has grown at a 33.9% compound annual growth rate (CAGR), from $39.22M to $94.2M.

What does TPIP external R&D expenses — R&D mean?

This metric represents the direct, third-party costs incurred specifically for the research and development of the TPIP (treprostinil palmitil inhalation powder) program. It captures expenditures related to clinical trials, contract research organizations, and external manufacturing or development activities associated with this specific pipeline asset. Monitoring these costs provides insight into the capital intensity and progress of the company's key late-stage clinical development programs.